Compare
Enlivex Ltd. vs Insmed Inc vs Alkermes plc. vs Opko Health, Inc.
| Latest fiscal year | Enlivex Ltd. ENLV | Insmed Inc INSM | Alkermes plc. ALKS | Opko Health, Inc. OPK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $606.42M | $1.48B | $606.88M |
| Revenue growth (YoY) | n/a | +66.7% | -5.2% | -14.9% |
| Gross margin | n/a | 79.7% (computed) | 86.7% (computed) | 33.9% |
| Operating margin | n/a | -205.6% | 17.2% | -19.3% |
| Net margin | n/a | -210.5% | 16.4% | -37.2% |
| Net income | $1.24B | -$1.28B | $241.66M | -$225.68M |
| EPS (Diluted) | $25.48 | -$6.42 | $1.43 | -$0.30 |
| Operating cash flow | -$10.42M | -$935.01M | $520.75M | -$178.54M |
| Free cash flow | -$10.48M | -$967.58M | $480.33M | -$190.82M |
| Cash & equivalents | $1.89M | $510.44M | $388.57M | $364.41M |
| Total assets | $2.33B | $2.26B | $2.49B | $1.93B |
| Total liabilities | $392.05M | $1.53B | $667.70M | $663.99M |
| Shareholders' equity | $1.93B | $738.98M | $1.82B | $1.27B |
| Return on year-end equity | 63.9% | -172.8% | 13.3% | -17.8% |
| Shares outstanding | 237.38M | 214.26M | 165.61M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Enlivex Ltd. | Insmed Inc | Alkermes plc. | Opko Health, Inc. |
|---|---|---|---|---|
| Latest | n/a | $606.42M Ended 2025-12-31 | $1.48B Ended 2025-12-31 | $606.88M Ended 2025-12-31 |
| 1 year earlier | n/a | $363.71M Ended 2024-12-31 | $1.56B Ended 2024-12-31 | $713.14M Ended 2024-12-31 |
| 2 years earlier | n/a | $305.21M Ended 2023-12-31 | $1.66B Ended 2023-12-31 | $863.50M Ended 2023-12-31 |
| 3 years earlier | n/a | $245.36M Ended 2022-12-31 | $1.11B Ended 2022-12-31 | $1.00B Ended 2022-12-31 |
| 4 years earlier | n/a | $188.46M Ended 2021-12-31 | $1.17B Ended 2021-12-31 | $1.77B Ended 2021-12-31 |